



February 10, 2026

To Whom It May Concern,

Company Name: Kubota Pharmaceutical Holdings Co., Ltd.

Title and Name of Representative: Ryo Kubota,

Representative Executive Officer,

Director, Chairman, President, and CEO

(TSE Growth: Code 4596)

Contact: Public Relations & Investor Relations, Administration Dept.

(TEL : 03-6550-8928 (main))

### Notice regarding Earnings Forecast

Kubota Pharmaceutical Holdings Co., Ltd. (the “Company”) hereby announces the consolidated earnings forecast for the fiscal year ending December 2025 (January 1, 2025 – December 31, 2025) as follows.

#### Records

##### 1. Consolidated Earnings Forecast for the Fiscal Year Ending December 2025 (January 1, 2025 – December 31, 2025)

	Revenue	Operating profit (loss)	Profit (loss) before tax	Net profit (loss)	Profit (loss) attributable to owners of parent	Basic earnings (loss) per share
	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Millions of yen	Yen
Previous forecast (A)	-	-	-	-	-	-
Revised forecast (B)	21	(877)	(659)	(659)	(659)	(11.69)
Change (B-A)	-	-	-	-	-	-
Percent change (%)	-	-	-	-	-	-
(Reference) Fiscal year ended December 31, 2024	27	(1,345)	(1,333)	(1,333)	(1,333)	(23.65)

##### 2. Reasons for the Revision of the Earnings Forecast

The Kubota Pharmaceutical Group (the “Group”) is promoting its businesses as outlined below with the aim of driving innovation in the treatment of myopia and ophthalmic diseases.

The “Kubota Glass<sup>®</sup>” business is focused on increasing brand awareness in Japan and expanding sales channels in overseas markets, particularly in Asia and Europe. In the fiscal year ending December 2025, the Group will continue marketing activities aimed at full-scale adoption and the development of next-generation devices, and business revenue is expected to reach JPY 21 million.

The “emixustat hydrochloride” business continues to analyze accumulated clinical data for indications, including Stargardt disease, and to engage in discussions with potential global strategic partners. The Group aims to achieve early monetization through measures such as utilizing compassionate use programs overseas.

Regarding profit and loss, operating loss is expected to be JPY 877 million due to the aforementioned upfront investments and the recognition of research and development (R&D) expenses. Meanwhile, the amount of loss at the



net income level is expected to be smaller than the operating loss due to the recording of non-operating income.

### 3. Future Outlook

With respect to “Kubota Glass<sup>®</sup>,” the Group is examining and preparing for the possibility of new sales approaches in the Japanese market with the aim of delivering the value of Kubota Glass in a more diverse and continuous manner. Regarding “emixustat hydrochloride,” the Group will continue to strive toward maximizing corporate value and building a framework for early profitability through the progress of licensing negotiations.

end